153 related articles for article (PubMed ID: 27729322)
41. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.
Paiva B; Martinez-Lopez J; Corchete LA; Sanchez-Vega B; Rapado I; Puig N; Barrio S; Sanchez ML; Alignani D; Lasa M; García de Coca A; Pardal E; Oriol A; Garcia ME; Escalante F; González-López TJ; Palomera L; Alonso J; Prosper F; Orfao A; Vidriales MB; Mateos MV; Lahuerta JJ; Gutierrez NC; San Miguel JF
Blood; 2016 Jun; 127(24):3035-9. PubMed ID: 27069257
[TBL] [Abstract][Full Text] [Related]
42. Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival.
Huang XF; Jian S; Lu JL; Shen KN; Feng J; Zhang CL; Tian Z; Wang JL; Lei WJ; Cao XX; Zhou DB; Liang ZY; Li J
Amyloid; 2020 Mar; 27(1):36-44. PubMed ID: 31635489
[No Abstract] [Full Text] [Related]
43. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
44. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
[TBL] [Abstract][Full Text] [Related]
45. Characterization and prognostic implication of delayed complete response in AL amyloidosis.
Muchtar E; Gertz MA; Kumar SK; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Lisa Hwa Y; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Vincent Rajkumar S; Kyle RA; Dispenzieri A
Eur J Haematol; 2021 Mar; 106(3):354-361. PubMed ID: 33230879
[TBL] [Abstract][Full Text] [Related]
46. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
Kaufman GP; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Leung N; Dingli D; Lust JA; Lin Y; Kapoor P; Go RS; Zeldenrust SR; Kyle RA; Rajkumar SV; Kumar SK
Am J Hematol; 2015 Mar; 90(3):181-6. PubMed ID: 25388651
[TBL] [Abstract][Full Text] [Related]
47. Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice.
Gupta R; Jevremovic D; Mathew SJ; Kumar S
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e88-e95. PubMed ID: 38142203
[TBL] [Abstract][Full Text] [Related]
48. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.
Peceliunas V; Janiulioniene A; Matuzeviciene R; Griskevicius L
Cytometry B Clin Cytom; 2011 Sep; 80(5):318-23. PubMed ID: 21634008
[TBL] [Abstract][Full Text] [Related]
49. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
[TBL] [Abstract][Full Text] [Related]
50. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.
Zhou P; Hoffman J; Landau H; Hassoun H; Iyer L; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):49-58. PubMed ID: 22100494
[TBL] [Abstract][Full Text] [Related]
51. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Merlini G; Palladini G
Blood; 2017 Aug; 130(5):625-631. PubMed ID: 28546143
[TBL] [Abstract][Full Text] [Related]
52. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
[TBL] [Abstract][Full Text] [Related]
53. Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
Bezdekova R; Jelinek T; Kralova R; Stork M; Polackova P; Vsianska P; Brozova L; Jarkovsky J; Almasi M; Boichuk I; Knechtova Z; Penka M; Pour L; Sevcikova S; Hajek R; Rihova L
Br J Haematol; 2021 Oct; 195(1):95-107. PubMed ID: 34500493
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
[TBL] [Abstract][Full Text] [Related]
55. A patient with AL amyloidosis with negative free light chain results.
Milani P; Valentini V; Ferraro G; Basset M; Russo F; Foli A; Palladini G; Merlini G
Clin Chem Lab Med; 2016 Jun; 54(6):1035-7. PubMed ID: 26677890
[TBL] [Abstract][Full Text] [Related]
56. Stereotactic Ablative Radiation Therapy for Pulmonary Recurrence-Based Oligometastatic Non-Small Cell Lung Cancer: Survival and Prognostic Value of Regulatory T Cells.
Liu C; Sun B; Hu X; Zhang Y; Wang Q; Yue J; Yu J
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1055-1064. PubMed ID: 31437470
[TBL] [Abstract][Full Text] [Related]
57. [Comparison of Different Staging Systems and Prognostic Analysis in 68 Cases of Primary Intestinal Diffuse Large B Cell Lymphoma].
Wang X; Wang CY; Xu W; Yang HL; Zhao HF; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):52-60. PubMed ID: 30738447
[TBL] [Abstract][Full Text] [Related]
58. Independent prognostic value of left ventricular mass index in patients with light-chain amyloidosis.
Huang H; He H; Qin Y; Du J; Song J
Acta Cardiol; 2022 Nov; 77(9):815-821. PubMed ID: 36196999
[TBL] [Abstract][Full Text] [Related]
59. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
60. Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis.
Matsuda M; Gono T; Shimojima Y; Hoshii Y; Ikeda S
Amyloid; 2003 Jun; 10(2):110-6. PubMed ID: 12964418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
